At the meeting, which took place electronically, the Management Committee was officially named, which will include María Jesús Lamas, director of the Spanish Agency for Medicines and Health Products (AEMPS). This body will be the one who makes the decisions about each advance purchase process, monitors the development of vaccines, and guarantees the transparency and good governance of the procurement and distribution process according to a clear regulatory framework.
The Management Committee yesterday selected a negotiating team, which will be made up of representatives from seven countries: Spain, Germany, France, the Netherlands, Sweden, Poland and Italy. The Spanish representative will be César Hernández, head of the department of medicines for human use of the AEMPS. This team will act as the sole interlocutor with the different companies that are developing candidates for the SARS-CoV-19 vaccine.
In this way, the Alliance and the countries that compose it seek to guarantee equitable access by all European citizens on equal terms to vaccines when they are available, ensuring that the entire purchasing and distribution process is carried out in a transparent manner, equitable and with the same safety and efficacy standards of the vaccine among all the member countries.
These decisions are the result of the agreement of the meeting of EU ministers that was held last Friday and in which the Minister of Health, Salvador Illa, participated, who expressed Spain's support for the Advance Purchase Agreement for Vaccines against COVID -19 from the European Union.
